INTERNATIONAL SEARCH REPORT

International application No

PCT/US04/33091

A CLASSIFICATION OF SUBJECT MATTER					
IPC C12N 5/06(2006 01),5/08(2006 01)					
USPC 435/370 According to International Patent Classification (IPC) or to both national classification and IPC					
B FIELDS SEARCHED					
	classification symbols)				
Minimum documentation searched (classification system followed by classification symbols) US 435/370					
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched					
Electronic data base consulted duping the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet					
C DOCUMENTS CONSIDERED TO BE RELEVANT					
Category Citation of document, with indication, where app	propriate, of the relevant passages	Relevant to claim No			
X JBS 5,665,589 (HARRIS et al) 9 September 1997 (09 09 1997), abstract, column 2, lines 16-		1-8,12-21, 23-25,28,30			
Y 25 column 3, lines 9, 13 and 24, column 4, lines 16 a	Y 25 column 3, lines 9, 13 and 24, column 4, lines 16 and 36, column 7, lines 43-67 9-1 1,22,26,27,29,31-				
51-65, column 8, lines 58-67, column 11, lines 48-56		1,4-8,12-22,30			
		2,3,9-1 1,23-29,31-34			
X MILLS et al Induction of drug metabolism enzymes and MDRI using a novel human hepatocyte cell line Journal of Pharmacology and Experimental Therapeutics April 2004, Vol 309 No 1, pages 303-309, especially abstract		1-31, 33 32, 34			
Y US 6,653,105 B2 (TRGLIA et al) 25 November 2003 (25 22 2005), column 2, lines 40-50, column 7, lines 1-15, column 8, line 20, column 9, lines 17-34, column 10, lines 27-32		1-34			
Further documents are listed in the continuation of Box C	U See patent family annex				
Special categories of cited documents	T tater document published after the inte date and not in conflict with the applic				
A document defining the general state of the ait which is not considered to be of particular relevance	principle or theory underlying the inve				
E earlier application or patent published on or after the international filing date	X document of particular relevance the considered novel or cannot be conside when the document is taken atone				
document which may throw doubts on priority claum(s) or which is cited to establish the publication date of another citation or other special reason (as specified) Y document of particular relevance the claimed timen from considered to involve an inventive step when the document combined with one or more other such documents such considered.		p when the document is a documents such combination			
O document referring to an oral disclosure use exhibition or other means	being obvious to a person skilled in th	e ari			
P document published pπor to the international filing date but later than the & document member of the same patent family priority date claimed					
	Date of the actual completion of the international search Date of mailing 4f the international report				
0 1 March 2006 (01 03 2006) Name and mailing address of the ISA/US Authorized officer					
Mail Stop PCT, Attn ISAUS		Thum of			
Commissioner for Patents P.O. Roy, 1450					
Alexandria, Virginia 22313-1450 Telephone No (571) 272-1600					
Facsimile No (571) 273-3201					

Form PCT/ISA/210 (second sheet) (Ap \pi 1 2005)

INTERNATIONAL SEARCH REPORT

International application No
PCT/US04/33091

Box No. I	Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)				
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons					
1	Claims Nos because they relate to subject matter not required to be searched by this Authority, namely				
2	Claims Nos because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be earned out, specifically				
3 1	Claims Nos because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 64(a)				
Box No.	Observations where unity of invention is lacking (Continuation of item 3 of first sheet)				
	ational Searching Authority found multiple inventions in this international application as follows Continuation Sheet				
1 1_	As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims				
2	2 As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of any additional fees				
As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos					
4 [X] No required additional search fees were timely paid by the applicant Consequently, this international search report is restπ cted to the invention first mentioned in the claims, it is covered by claims Nos 1-34					
Remark	on Protest The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee				
	The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation				
	1 1 No protest accompanied the payment of additional search fees				

Form PCT/ISA/210 (continuation of first sheet(2)) (Apπ1 2005)

TNTERNZ	TAMOTTA	SEARCH	REPORT

International application No PCT/US04/33091

BOX 111 OBSERVATIONS WHERE UNITY Or INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13 1 In order for all inventions to be examined, the approprate additional examination fees must be paid

Group I, claim(s) 1-34, drawn to a virally-immortilized hepatocyte

Group II, claim(s) 35-40, drawn to a first method of using a virally-immortilized hepatocyte for accessing effects of a chemical entity on a liver

Group III, claim(s) 41-45, drawn to a second method of using a virally-immortihzed hepatocyte for accessing enzyme induction

Group IV claim(s) 46-50 drawn to a third method of using a virally-immortihzed hepatocyte for accessing cellular toxicity

Group V, claim(s) 5 1-57, drawn to a fourth method of using a virally-immortilized hepatocyte for accessing effects of a liver on a chemical entity

Group VI, claim(s) 58, drawn to 22 various assays procedures wherein each procedure is relied upon on the use of a virally-immortilized hepatocyte

This application contains claims directed to more than one species of the gene π c invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13 1

In order for more than one species to be examined, the appropriate additional examination fees must be paid. The species are as follows the species are different assays 1 through 22 as recited in claim 58. The following claim(s) are/is gene π c 58.

The inventions listed as the Groups I through VI and the species 1 through 22 within the Group VI do not relate to a single general inventive concept under PCT Rule 13 1 because, under PCT Rule 13 2, they lack the same or corresponding special technical features for the following reasons

The special technical feature such as a virally-immortalized hepatocyte is known in the prior art For example US 6,107, 043 and US 6,046, 050 discloses virally-immortalized hepatocytes that are derived from normal liver cells, non-tumorogenic and have normal metabolic activity and/or produce plasma proteins (see abstracts)

Thus, the corresponding special technical feature is known and, therefore, unity of inventions is broken

Form PCT/ISA/210 (extra sheet) (April 2005)

INTERNATIONAL SEARCH REPORT	International application No PCT/US04/33091
Continuation of B FIELDS SEARCHED Item 3 WEST USPT, PGPUB, STN BIOSIS, NEDLINE, search terra immortalized hepatic cells, nontumoπgenic, SV40 TAG, nontumoP4 clotting factors, drug testing	50, plasma proteins, albumin, antitrypsin, transferrin,

Form PCT/ISA/210 (extra sheet) (April 2005)